SH-11037
SH-11037 is a potent inhibitor of soluble epoxide hydrolase (sEH) and docks to the substrate binding cleft in the sEH hydrolase domain. SH-11037 dose-dependently suppresses angiogenesis in the choroidal sprouting assay ex vivo and inhibited ocular developmental angiogenesis in zebrafish larvae. SH-11037 reduces choroidal neovascularisation lesion volume in the laser-induced CNV mouse model. SH-11037 synergises with anti-VEGF treatments in vitro and in vivo. SH-11037 induces G2/M phase blockade and retains retinal endothelial cell viability at active concentrations without overt toxicity. SH-11037 can be used for the research of retinal neovascularization and ocular neovascularization.
For research use only. We do not sell to patients.
- CAS No.: 1638153-78-2
- Formula: C34H39NO10
- Molecular Weight:621.67
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
sEH |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| ARPE-19 | GI50 |
100 μM
Compound: SH-11037
|
Cytotoxicity against human ARPE-19 cells assessed as cell growth inhibition incubated for 44 hrs by AlamarBlue reagent based fluorescence assay
Cytotoxicity against human ARPE-19 cells assessed as cell growth inhibition incubated for 44 hrs by AlamarBlue reagent based fluorescence assay
|
[PMID: 36938984] |
SH-11037 (14a) potently and selectively inhibits the proliferation of human microvascular retinal endothelial cells (HRECs) with a GI50 of 0.055 μM, showing ~14-fold selectivity over HUVECs, >1000-fold selectivity over 92-1 cells, and ~218-fold selectivity over Y79 cells[1].
SH-11037 dose-dependently inhibits human microvascular retinal endothelial cell (HREC) proliferation without inducing apoptotic nuclear changes[1].
SH-11037 (30-600 nM) dose-dependently inhibits the migration of human microvascular retinal endothelial cells (HRECs) in a scratch wound assay, with significant inhibition observed at concentrations ≥300 nM[1].
SH-11037 (30-500 nM) dose-dependently inhibits the tube formation of human microvascular retinal endothelial cells (HRECs) on Matrigel, with significant inhibition observed at concentrations ≥100 nM[1].
SH-11037 (50-600 nM) induces minimal apoptosis in human microvascular retinal endothelial cells (HRECs), with <10% of cells undergoing apoptosis at concentrations up to 600 nM[1].
SH-11037 (30-1000 nM) does not reduce the viability of human microvascular retinal endothelial cells (HRECs)[1].
SH-11037 (100-1000 nM; 48 h) causes a dose-dependent G2/M phase cell cycle arrest in human microvascular retinal endothelial cells (HRECs) without significant induction of apoptosis[1].
SH-11037 (1 μM; up to 2 h) is stable in pH 7.4 phosphate buffer but undergoes rapid, quantitative enzymatic hydrolysis to SH-11008 in mouse plasma (half-life 0.018 min) and slower hydrolysis in dog (half-life 69.1 min) and human plasma (half-life 73.2 min)[2].
SH-11037 (1 μM; up to 2 h) has carboxylesterase as the predominant enzyme mediating rapid hydrolysis to SH-11008 in mouse plasma and mouse eye homogenate; paraoxonase 1 and butyrylcholinesterase mediate slower hydrolysis in dog plasma, while only paraoxonase 1 mediates hydrolysis in human plasma[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human microvascular retinal endothelial cells
-
Concentration:100 nM; 300 nM; 1000 nM
-
Incubation Time:48 h
-
Result:Arrested HRECs at the G2/M phase of the cell cycle.
SH-11037 (1-10 μM) inhibits ocular angiogenesis in zebrafish larvae[4].
SH-11037 (0.1-100 μM; i.v.; single dose) has no toxic effects to eye[4].
SH-11037 (0.1-10 μM; i.v.; single dose) dose-dependently suppresses choroidal neovascularisation (CNV) lesion volume[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ICR (male, 8 weeks old, 30~35 g)[2]
-
Dosage:5 mg/kg
-
Administration:i.v.; single dose
-
Result:Exhibited plasma levels below quantitation limit (<0.24 ng/mL) throughout 24-hour time course.
Produced hydrolytic metabolite with peak concentration (Cmax) of 738.1 ng/mL at 5 minutes, area under the curve (AUCinf) of 14,728.5 ng·min/mL, and half-life (t1/2) of 3.6 minutes, detected above quantitation limit up to 30 minutes.
Reached fraction converted to fm of 102.7%.
-
Animal Model:ICR (male, 8 weeks old, 30~35 g)[2]
-
Dosage:10 mg/kg
-
Administration:p.o.; single dose
-
Result:Showed plasma levels below quantitation limit throughout 24-hour time course.
-
Animal Model:C57BL/6J (female, 6-8 weeks)[4]
-
Dosage:0.1 μM; 1 μM; 10 μM; 100 μM
-
Administration:i.v.; single dose
-
Result:Showed no histological changes in retinal sections.
Showed no morphological changes to retinal thickness.
Showed no signs of retinal injury, apoptosis or inflammation.
-
Animal Model:C57BL/6J (female, 6-8 weeks)[4]
-
Dosage:0.1 μM; 0.3 μM; 1 μM; 10 μM
-
Administration:i.v.; single dose
-
Result:Reduced CNV lesion size at 1 and 10 μM compared to vehicle controls.
Reduced leakiness of CNV lesions relative to the vehicle treatment.
Chemical Information
-
CAS No. 1638153-78-2
-
Molecular Weight 621.67
-
Formula C34H39NO10
-
SMILES
COC1=C2C(OCC(C2=O)CC3=CC(OC([C@@H](NC(OC(C)(C)C)=O)CC4=CC=CC=C4)=O)=C(C=C3)OC)=CC(OC)=C1OC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Basavarajappa HD, et al. Synthesis and Biological Evaluation of Novel Homoisoflavonoids for Retinal Neovascularization. J Med Chem. 2015;58(12):5015-5027. [Content Brief]
[2]. Kim EY, et al. Mouse Pharmacokinetics and In Vitro Metabolism of SH-11037 and SH-11008, Synthetic Homoisoflavonoids for Retinal Neovascularization. Pharmaceutics. 2022;14(11):2270. Published 2022 Oct 24. [Content Brief]
[3]. Sulaiman RS, et al. Chemical Proteomics Reveals Soluble Epoxide Hydrolase as a Therapeutic Target for Ocular Neovascularization. ACS Chem Biol. 2018 Jan 19;13(1):45-52. [Content Brief]
[4]. Sulaiman RS, et al. A novel small molecule ameliorates ocular neovascularisation and synergises with anti-VEGF therapy. Sci Rep. 2016 May 5;6:25509. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz